| 臺大學術典藏 |
2021-03-09T06:46:15Z |
Prognostic value of multidrug resistance 1, glutathione-S-transferase-�k and p53 in advanced nasopharyngeal carcinoma treated with systemic chemotherapy
|
Hsu C.-H.;Chen C.-L.;Ruey-Long Hong;Chen K.-L.;Lin J.-F.;Cheng A.-L.; Hsu C.-H.; Chen C.-L.; RUEY-LONG HONG; Chen K.-L.; Lin J.-F.; Cheng A.-L. |
| 臺大學術典藏 |
2021-03-09T06:46:06Z |
Factors impacting prognosis prediction in BCLC stage C and Child-Pugh Class A hepatocellular carcinoma patients in prospective clinical trials of systemic therapy
|
Lin Z.-Z.; Hsu C.; Hu F.-C.; Shao Y.-Y.; Chang D.-Y.; Yang C.-H.; RUEY-LONG HONG; Hsu C.-H.; Chengb A.-L. |
| 臺大學術典藏 |
2021-03-09T05:18:40Z |
Weekly gemcitabine plus 24-h infusion of high-dose 5-fluorouracil/ leucovorin for locally advanced or metastatic carcinoma of the biliary tract
|
Hsu C.; Ying-Chun Shen; Yang C.-H.; Yeh K.-H.; Lu Y.-S.; Hsu C.-H.; Liu H.-T.; Li C.-C.; Chen J.-S.; Wu C.-Y.; Cheng A.-L. |
| 臺大學術典藏 |
2021-03-09T05:18:37Z |
Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma
|
Hsu C.-H.; Ying-Chun Shen; Lin Z.-Z.; Chen P.-J.; Shao Y.-Y.; Ding Y.-H.; Hsu C.; Cheng A.-L. |
| 臺大學術典藏 |
2021-03-09T05:18:36Z |
Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma
|
Shao Y.-Y.; Lin Z.-Z.; Hsu C.; Ying-Chun Shen; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2021-03-09T05:18:35Z |
Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil
|
Hsu C.-Y.; Ying-Chun Shen; Yu C.-W.; Hsu C.; Hu F.-C.; Hsu C.-H.; Chen B.-B.; Wei S.-Y.; Cheng A.-L.; Shih T.T.-F. |
| 臺大學術典藏 |
2021-03-09T05:18:34Z |
High circulating endothelial progenitor levels associated with poor survival of advanced hepatocellular carcinoma patients receiving sorafenib combined with metronomic chemotherapy
|
Shao Y.-Y.; Lin Z.-Z.; Chen T.-J.; Hsu C.; Ying-Chun Shen; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2021-03-09T05:18:33Z |
Prognosis of advanced hepatocellular carcinoma patients enrolled in clinical trials can be classified by current staging systems
|
Shao Y.-Y.; Lu L.-C.; Lin Z.-Z.; Hsu C.; Ying-Chun Shen; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2021-03-09T05:18:31Z |
Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
|
Lu L.-C.; Hsu C.; Shao Y.-Y.; Chao Y.; Yen C.-J.; Shih I.-L.; Hung Y.-P.; Chang C.-J.; Ying-Chun Shen; Guo J.-C.; Liu T.-H.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2021-03-09T05:18:31Z |
Considerations of heterogeneity in clinical trials for hepatocellular carcinoma
|
Liu T.-H.; Shao Y.-Y.; Lu L.-C.; Ying-Chun Shen; Hsu C.; Lin Z.-Z.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2021-03-09T05:18:30Z |
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS�VESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO
|
Chen L.-T.; Martinelli E.; Cheng A.-L.; Pentheroudakis G.; Qin S.; Bhattacharyya G.S.; Ikeda M.; Lim H.-Y.; Ho G.F.; Choo S.P.; Ren Z.; Malhotra H.; Ueno M.; Ryoo B.-Y.; Kiang T.C.; Tai D.; Vogel A.; Cervantes A.; Lu S.-N.; Yen C.-J.; Huang Y.-H.; Chen S.-C.; Hsu C.; Ying-Chun Shen; Tabernero J.; Yen Y.; Hsu C.-H.; Yoshino T.; Douillard J.-Y. |
| 臺大學術典藏 |
2021-03-09T05:18:29Z |
A Multicenter Phase II Study of Second-Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First-Line Sorafenib Monotherapy
|
Lin Z.-Z.; Chen B.-B.; Hung Y.-P.; Huang P.-H.; Ying-Chun Shen; Shao Y.-Y.; Hsu C.-H.; Cheng A.-L.; Lee R.-C.; Chao Y.; Hsu C. |
| 臺大學術典藏 |
2021-03-05T06:07:25Z |
Induction chemotherapy with gemcitabine, oxaliplatin, and 5-fluorouracil/leucovorin followed by concomitant chemoradiotherapy in patients with locally advanced pancreatic cancer: A Taiwan cooperative oncology group phase II study
|
Ch'Ang H.-J.; Lin Y.-L.; Wang H.-P.; Chiu Y.-F.; MING-CHU CHANG; Hsu C.-H.; Tien Y.-W.; Chen J.-S.; Hsieh R.-K.; Lin P.-W.; Shan Y.-S.; Cheng A.-L.; Chang J.-Y.; Whang-Peng J.; Hwang T.-L.; Chen L.-T. |
| 臺大學術典藏 |
2021-03-04T07:50:46Z |
Inhibiting autophagy potentiates the antitumor efficacy of Euphorbia royleana for canine mammary gland tumors
|
Huang, Y.-Y.;Chen, C.-H.;Hsu, C.-H.;Kuo, T.-Y.;Liu, C.-C.;Liao, A.T.-C.;Liao, A.T.-C.;Lin, C.-S.;Lin, C.-S.; Huang, Y.-Y.; Chen, C.-H.; Hsu, C.-H.; Kuo, T.-Y.; Liu, C.-C.; Liao, A.T.-C.; Liao, A.T.-C.; Lin, C.-S.; Lin, C.-S.; CHEN-SI LIN |
| 臺大學術典藏 |
2021-03-04T02:36:03Z |
Prognostic Factors for Metastatic Urothelial Carcinoma Treated with Cisplatin and 5-Fluorouracil-Based Regimens
|
Lin C.-C.;Hsu C.-H.;Huang C.-Y.;Yu-Chieh Tsai;Huang K.-H.;Cheng A.-L.;Pu Y.-S.; Lin C.-C.; Hsu C.-H.; Huang C.-Y.; YU-CHIEH TSAI; Huang K.-H.; Cheng A.-L.; Pu Y.-S. |
| 臺大學術典藏 |
2021-03-04T02:36:02Z |
Gemcitabine and ifosfamide as a second-line treatment for cisplatin-refractory metastatic urothelial carcinoma: A phase II study
|
Lin C.-C.;Hsu C.-H.;Huang C.-Y.;Keng H.-Y.;Yu-Chieh Tsai;Huang K.-H.;Cheng A.-L.;Pu Y.-S.; Lin C.-C.; Hsu C.-H.; Huang C.-Y.; Keng H.-Y.; YU-CHIEH TSAI; Huang K.-H.; Cheng A.-L.; Pu Y.-S. |
| 臺大學術典藏 |
2021-03-04T02:36:02Z |
Multifractionated paclitaxel and cisplatin combined with 5-fluorouracil and leucovorin in patients with metastatic or recurrent esophageal squamous cell carcinoma
|
Lin C.-C.;Yeh K.-H.;Yang C.-H.;Hsu C.;Yu-Chieh Tsai;Hsu W.-L.;Cheng A.-L.;Hsu C.-H.; Lin C.-C.; Yeh K.-H.; Yang C.-H.; Hsu C.; YU-CHIEH TSAI; Hsu W.-L.; Cheng A.-L.; Hsu C.-H. |
| 臺大學術典藏 |
2021-03-04T02:36:01Z |
Induction Cisplatin and Fluorouracil-Based Chemotherapy Followed by Concurrent Chemoradiation for Muscle-Invasive Bladder Cancer
|
Lin C.-C.; Hsu C.-H.; Cheng J.C.; Huang C.-Y.; YU-CHIEH TSAI; Hsu F.-M.; Huang K.-H.; Cheng A.-L.; Pu Y.-S. |
| 臺大學術典藏 |
2021-03-04T02:36:01Z |
Improved local control by surgery and paclitaxel-based chemoradiation for esophageal squamous cell carcinoma: Results of a retrospective non-randomized study
|
Hsu F.-M.; Lin C.-C.; Lee J.-M.; Chang Y.-L.; Hsu C.-H.; YU-CHIEH TSAI; Lee Y.-C.; Cheng J.C.-H. |
| 臺大學術典藏 |
2021-03-04T02:36:01Z |
Association of clinical and dosimetric factors with postoperative pulmonary complications in esophageal cancer patients receiving intensity-modulated radiation therapy and concurrent chemotherapy followed by thoracic esophagectomy
|
Hsu F.-M.; Lee Y.-C.; Lee J.-M.; Hsu C.-H.; Lin C.-C.; YU-CHIEH TSAI; Wu J.-K.; Cheng J.C.-H. |
| 臺大學術典藏 |
2021-03-04T02:36:00Z |
Retrospective analysis of outcome differences in preoperative concurrent chemoradiation with or without elective nodal irradiation for esophageal squamous cell carcinoma
|
Hsu F.-M.;Lee J.-M.;Huang P.-M.;Lin C.-C.;Hsu C.-H.;Yu-Chieh Tsai;Lee Y.-C.;Chia-Hsien Cheng J.; Hsu F.-M.; Lee J.-M.; Huang P.-M.; Lin C.-C.; Hsu C.-H.; YU-CHIEH TSAI; Lee Y.-C.; Chia-Hsien Cheng J. |
| 臺大學術典藏 |
2021-03-04T02:35:58Z |
MLN4924, a novel protein neddylation inhibitor, suppresses proliferation and migration of human urothelial carcinoma: In vitro and in vivo studies
|
Kuo K.-L.; Ho I.-L.; Shi C.-S.; Wu J.-T.; Lin W.-C.; YU-CHIEH TSAI; Chang H.-C.; Chou C.-T.; Hsu C.-H.; Hsieh J.-T.; Chang S.-C.; Pu Y.-S.; Huang K.-H. |
| 臺大學術典藏 |
2021-03-04T02:35:57Z |
MLN4924 synergistically enhances cisplatin-induced cytotoxicity via jnk and bcl-xl pathways in human urothelial carcinoma
|
Ho I.-L.; Kuo K.-L.; Liu S.-H.-.; Chang H.-C.; Hsieh J.-T.; Wu J.-T.; Chiang C.-K.; Lin W.-C.; YU-CHIEH TSAI; Chou C.-T.; Hsu C.-H.; Pu Y.-S.; Shi C.-S.; Huang K.-H. |
| 臺大學術典藏 |
2021-03-04T02:35:55Z |
A role of multimodality bladder-preserving therapy in patients with muscle-invasive bladder cancer plus hydronephrosis with or without pelvic nodal involvement
|
Chiang Y.;Cheng J.C.-H.;Huang C.-Y.;Yu-Chieh Tsai;Lin C.-C.;Hsu C.-H.;Cheng A.-L.;Pu Y.-S.; Chiang Y.; Cheng J.C.-H.; Huang C.-Y.; YU-CHIEH TSAI; Lin C.-C.; Hsu C.-H.; Cheng A.-L.; Pu Y.-S. |
| 臺大學術典藏 |
2021-02-25T07:00:59Z |
The unique characteristic in peripheral immune cells in patients with advanced hepatocellular carcinoma
|
Hung Y.-P.;Yu-Yun Shao;Hsu C.;Hsu C.-H.;Lee J.-M.;Yang M.-H.;Chao Y.; Hung Y.-P.; YU-YUN SHAO; Hsu C.; Hsu C.-H.; Lee J.-M.; Yang M.-H.; Chao Y. |
